Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that a patent for its DNA ImmunoBody® technology has been granted in Japan. This key patent follows approval in Australia earlier this year and adds to Scancell’s growing body of intellectual property for its ImmunoBody® platform. Scancell’s protein ImmunoBody® patent has already been approved in the US, Europe, Japan and Australia.
Dr. Richard Goodfellow, Joint Chief Executive of Scancell, commented:
“This Japanese approval is an important addition as we continue to build a comprehensive IP portfolio for our ImmunoBody® platforms. With the positive results from our SCIB1 study announced earlier this week and the progress we are making on our Moditope® programme, IP plays an increasingly important role in the value ascribed to Scancell’s technology. We look forward to building on the momentum of Scancell’s progress in 2014.”
For Further Information:
| Dr Richard Goodfellow, Joint CEO |
Scancell Holdings Plc |
+ 44 (0) 20 7831 3113 |
| Professor Lindy Durrant, Joint CEO |
Scancell Holdings Plc |
|
| Camilla Hume/Stephen Keys |
Cenkos Securities plc |
+ 44 (0) 20 7397 8900 |
| Mo Noonan/Simon Conway |
FTI Consulting |
+ 44 (0) 20 7831 3113 |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and has just completed Phase 1/2 clinical trials which demonstrated that SCIB1 produced a melanoma-specific immune response and promising survival trend. A further higher dose study of SCIB1 will take place during 2014.
Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.